MedTrace Logo

The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex

NCT06686914 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-10-31

No results posted yet for this study

Summary

The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.

Conditions

  • Cannabidiol Effects
  • Driving Performance

Interventions

DRUG

Cannabidiol (CBD) Oil 300mg

Cannabidiol (CBD) Oil 300mg, 1 dose

DRUG

Cannabidiol (CBD) Oil 150mg

Cannabidiol (CBD) Oil 150mg, 1 dose

DRUG

Placebo Oil

Placebo Oil, 1 dose

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • West Virginia University

    lead OTHER

Principal Investigators

  • Toni M Rudisill, PhD · West Virginia University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2028-12-31
Completion
2029-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686914 on ClinicalTrials.gov